Guggenheim Reiterates Buy Rating for Nanobiotix (NASDAQ:NBTX)

Nanobiotix (NASDAQ:NBTX)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a report issued on Tuesday, Benzinga reports. They presently have a $64.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 79.12% from the company’s current price.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Leerink Partners boosted their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nanobiotix presently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Trading Down 3.5%

NASDAQ NBTX opened at $35.73 on Tuesday. The stock has a 50-day simple moving average of $39.58 and a 200 day simple moving average of $37.20. Nanobiotix has a 12 month low of $9.32 and a 12 month high of $57.14.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.